Education
About Us
Working with TipRanks
Follow Us
Immunovant, Inc. (IMVT)
:IMVT
Total Valuation
Immunovant has a market cap or net worth of $2.44B. The enterprise value is $3.26B.
Market Cap$2.44B
Enterprise Value$3.26B
Share Statistics
Immunovant has 169.86M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding169.86M
Owened by Insiders2.73%
Owened by Instutions24.73%
Financial Efficiency
Immunovant’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -45.84%.
Return on Equity (ROE)-41.98%
Return on Assets (ROA)-38.92%
Return on Invested Capital (ROIC)-45.84%
Return on Capital Employed (ROCE)-45.76%
Revenue Per Employee$7,246.377
Profits Per Employee-$1,848,840.58
Employee Count207
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunovant is -16.83. Immunovant’s PEG ratio is -1.69.
PE Ratio-16.83
PS Ratio0.00
PB Ratio7.07
Price to Fair Value7.07
Price to FCF-20.34
Price to Operating Cash Flow-20.38
PEG Ratio-1.69
Income Statement
In the last 12 months, Immunovant had revenue of $1.50M and earned -$382.71M in profits. Earnings per share was -$2.62.
Revenue$1.50M
Gross Profit$1.36M
Operating Income-$405.20M
Pretax Income-$382.17M
Net Income-$382.71M
EBITDA-404.87M
Earnings Per Share (EPS)-2.62
Cash Flow
In the last 12 months, operating cash flow was -$324.94M and capital expenditures -$708.00K, giving a free cash flow of -$325.64M billion.
Operating Cash Flow-$324.94M
Free Cash Flow-$325.64M
Free Cash Flow per Share-$1.92
Dividends & Yields
Immunovant pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-4.92%
Earnings Yield-5.94%
Stock Price Statistics
Beta0.99
52-Week Price Change-56.90%
50-Day Moving Average19.30
200-Day Moving Average26.04
Relative Strength Index (RSI)28.92
Average Volume (3m)1.98M
Important Dates
Immunovant upcoming earnings date is May 28, 2025, Before Open.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 28, 2025
Ex-Dividend Date―
Financial Position
Immunovant as a current ratio of 13.70, with Debt / Equity ratio of <0.01
Current Ratio13.70
Quick Ratio13.70
Debt to Market Cap<0.01
Net Debt to EBITDA2.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunovant has paid $539.00K in taxes.
Income Tax$539.00K
Effective Tax Rate-0.22%
Enterprise Valuation
Immunovant EV to EBITDA ratio is -13.82, with an EV/FCF ratio of -17.38.
EV to Sales0.00
EV to EBITDA-13.82
EV to Free Cash Flow-17.38
EV to Operating Cash Flow-17.41
Balance Sheet
Immunovant has $374.69M in cash and marketable securities with $23.00K in debt, giving a net cash position of -$374.66M billion.
Cash & Marketable Securities$374.69M
Total Debt$23.00K
Net Cash-$374.66M
Net Cash Per Share-$2.21
Tangible Book Value Per Share$4.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunovant is $47.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$47.50
Price Target Upside256.87%
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast
EPS Growth Forecast-43.10%